Metaphore Biotechnologies Announces Formation of Scientific Advisory Board to Advance the Next Era of Antibody Medicines
Metaphore Biotechnologies (“Metaphore”), a Flagship Pioneering company creating new antibody-based medicines, today announced the formation of its Scientific Advisory Board (SAB). The SAB brings expertise across protein engineering, AI/ML, immunology, metabolism, and biologics development as Metaphore advances its integrated experimental and computational antibody design platform and initial pipeline of therapeutics to the clinic.
Antibodies are one of medicine’s most important drug classes, but most have historically acted through one dominant action: blocking biology. Metaphore is expanding what antibodies can do. Powered by an integrated platform combining a proprietary experimental functional data engine with a mechanism-aware computational engine, Metaphore is designing antibodies with unique mechanisms to activate, tune and engage biology in entirely new ways.
“We are entering an important stage for Metaphore, as our platform begins to translate into therapeutic programs that show what functional antibody design can make possible,” said Anabella Villalobos, Ph.D., Chief Scientific Officer of Metaphore. “This Scientific Advisory Board brings together leaders who understand how to turn breakthrough science into medicines, and their guidance will be invaluable as we continue advancing our platform, pipeline, and long-term vision for antibody-based medicines.”
